Intersect ENT (NASDAQ:XENT) is set to release its earnings data after the market closes on Monday, February 26th. Analysts expect Intersect ENT to post earnings of ($0.17) per share for the quarter.
Shares of Intersect ENT (NASDAQ:XENT) opened at $36.05 on Friday. The stock has a market cap of $1,060.00, a P/E ratio of -58.15 and a beta of 0.78. Intersect ENT has a one year low of $12.50 and a one year high of $38.30.
A number of research firms have issued reports on XENT. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Northland Securities reiterated a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a research note on Friday, November 3rd. BidaskClub upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating in a research note on Monday, February 5th. Zacks Investment Research cut shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Finally, Guggenheim restated a “buy” rating and issued a $41.00 price objective on shares of Intersect ENT in a research note on Friday, December 15th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $33.38.
In related news, COO Richard E. Kaufman sold 50,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $33.33, for a total transaction of $1,666,500.00. Following the completion of the transaction, the chief operating officer now directly owns 107,470 shares in the company, valued at approximately $3,581,975.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Richard E. Kaufman sold 958 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $37.21, for a total transaction of $35,647.18. Following the transaction, the chief operating officer now owns 87,512 shares of the company’s stock, valued at $3,256,321.52. The disclosure for this sale can be found here. Insiders sold 172,310 shares of company stock valued at $5,764,037 over the last 90 days. 13.70% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/02/24/intersect-ent-xent-scheduled-to-post-earnings-on-monday.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.